PD-1 inhibitor-induced systemic sclerosis with early interstitial lung disease and autoimmune thyroiditis in advanced gastric cancer: a case report and literature review
{{output}}
Immune checkpoint inhibitors (ICIs) have revolutionized anti-tumor therapy, yet their use is increasingly complicated by immune-related adverse events (irAEs). We present a rare case in which sequential administration of two PD-1 inhibitors (ICIs), Camrelizuma... ...
